SCHEMBL5047166

SCHEMBL5047166

CC1(C)CCC(C)(C)c2c(OCc3ccc(F)cc3)cc(C=O)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.48
MAOA P21397 4/20 0.48
TACR2 P21452 1/20 0.39
PTPN1 P18031 4/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
HPD P32754 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HTR1A P08908 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
POLB P06746 2/20 0.37
RECQL P46063 1/20 0.37
CISD1 Q9NZ45 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5050784 0.89 MAOA (0.49) MAOBMAOATACR2ALDH1A1SMN1; SMN2
SCHEMBL5044087 0.87 PTPN1 (0.41) MAOBMAOATACR2PTPN1ALDH1A1
SCHEMBL5048414 0.86 L3MBTL1 (0.38) MAOBMAOATACR2ALDH1A1SMN1; SMN2
SCHEMBL6438536 0.80 MAOB (0.43) MAOBMAOAALDH1A1SMN1; SMN2HPD
SCHEMBL3068905 0.76 FDPS (0.42) ALDH1A1SMN1; SMN2HPGD
SCHEMBL5048446 0.75 MAOB (0.52) MAOBMEN1KMT2A
SCHEMBL5048445 0.75 MAOB (0.52) MAOBMEN1KMT2A
SCHEMBL5049671 0.74 MAOB (0.36) MAOBMAOAALDH1A1SMN1; SMN2HPD
SCHEMBL3062968 0.74 FDPS (0.38) ALDH1A1SMN1; SMN2L3MBTL1POLBRECQL
SCHEMBL5047257 0.74 MAOB (0.48) MAOBALDH1A1L3MBTL1POLBRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG MAOB 2084/4885MAOA 2011/4885TACR2 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.